Drug Discovery - Publications - Faculty & Research - Harvard Business School

Filter Results: (64)

Filter Results: (64)

Show Results For

← Page 2 of 64 Results →

Sort by

Are you looking for?

→Search All HBS Web

September 2020
Case

Minerva 2004: Discovery

By: John R. Wells and Benjamin Weinstock

After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for... View Details

Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry

Article

Strategic Assets, Interdependence and Technological Change: An Empirical Investigation of Complementarity in Pharmaceutical Drug Discovery

By: S. Thomke and W. Kuemmerle

Keywords: Strategy; Assets; Information Technology; Change; Information; Health; Pharmaceutical Industry

Find at Harvard

2004
Article

Do Firms Change Capabilities by Hiring New People? A Study of the Adoption of Science-based Drug Discovery

By: Rebecca M. Henderson, Nicola Lacetera and Iain Cockburn

Keywords: Selection and Staffing; Change; Science; Health; Information

Find at Harvard

October 1997 (Revised September 2003)
Case

Eli Lilly and Company: Drug Development Strategy (A)

By: Stefan H. Thomke, Ashok Nimgade and Paul Pospisil

Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of "combinatorial chemistry"--a rapidly emerging and revolutionary approach to preclinical drug discovery. The product manager of a potential blockbuster migraine drug... View Details

Keywords: Chemicals; Finance; Innovation and Invention; Time Management; Markets; Product Development; Organizations; Business Processes; Problems and Challenges; Business and Stakeholder Relations; Competition; Pharmaceutical Industry

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

November 2016
Case

Anthony Starks at InSiL Therapeutics (A)

By: Gary Pisano and Vicki Sato

When Bruce Wayne hired Anthony Starks, he thought he had hit a home run by getting the most brilliant and passionate scientist-leader in the field to be his CSO. But a few months in, Wayne and Starks begin to clash over crucial forward-looking decisions about the... View Details

Keywords: Biotech; Silicon; Managing Innovation; Management Challenges; Managing People; Managing Organization; R＆D; R＆D Project Management; Platform; Venture Capital; Drug Discovery; management; Biotechnology Industry; California

February 2007 (Revised April 2010)
Case

Wyeth Pharmaceuticals: Spurring Scientific Creativity with Metrics

By: Robert S. Huckman, Gary P. Pisano and Mark Rennella

Describes the reorganization of the drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics--jointly affecting all R&D scientists--for the progression... View Details

Keywords: Decision Making; Measurement and Metrics; Business Processes; Organizational Structure; Research and Development; Science-Based Business; Creativity; Pharmaceutical Industry

November 2019 (Revised April 2020)
Technical Note

The Life Sciences Revolution: A Technical Primer

By: Gary P. Pisano, William J. Anderson, Amitabh Chandra, Clarissa Ceruti and Stephanie Oestreich

For more than two decades, scientific advances have been driving profound changes in drug discovery and the drug industry itself. This case provides an overview and description of these technical and scientific advances. Written for the nonscientific reader, it may be... View Details

Keywords: Science; Technological Innovation; Technology; Pharmaceutical Industry; Biotechnology Industry

September 1999 (Revised September 2005)
Case

Strategic Deal Making at Millennium Pharmaceuticals

A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug... View Details

Keywords: Alliances; Negotiation Deal; Growth and Development Strategy; Pharmaceutical Industry; Cambridge

June 2004 (Revised June 2006)
Supplement

Vertex Pharmaceuticals: R&D Portfolio Management (A)

By: Gary P. Pisano, Lee Fleming and Eli Strick

Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details

Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry

2024
Working Paper

Cephalosporins—Fighting Hospital Infections: Case Histories of Transformational Advances

By: Amar Bhidé, Srikant Datar and Katherine Stebbins

This case history describes the development of three generations of cephalosporins – antibiotics that have significantly reduced hospital infections. Specifically, we chronicle how: 1) Early (pre-cephalosporin) antibiotics were developed in the first half of the 20th... View Details

Keywords: Health Care and Treatment; Technological Innovation; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Innovation and Invention; Governing Rules, Regulations, and Reforms

October 2013
Case

FasterCures: Removing Barriers to Treatments

By: Richard G. Hamermesh and James Weber

In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details

September 2023 (Revised April 2024)
Case

Atomwise: Strategic Opportunities in AI for Pharma

By: Satish Tadikonda

Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details

Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Pharmaceutical Industry

April 2002
Case

In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen

By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok

Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed... View Details

Keywords: Change; Decisions; Product Development; Research and Development; Expansion; Technology; Biotechnology Industry

September 2024
Case

Google Quantum AI

By: David B. Yoffie, Michael A. Cusumano and Matt Higgins

Quantum computing may be the most important nascent computing technology of the 21st century. It has the potential to impact industries ranging from drug discovery to cybersecurity. Google's Quantum AI is one of the leaders in quantum research. This case explores... View Details

Keywords: Information Technology Industry

March 2008
Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington

Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details

Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry

July 2024
Case

Gates Ventures: Making Alzheimer's a Forgotten Past

By: Satish Tadikonda, William Marks, Shardule Shah and Calvin Marambo

After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the... View Details

September 2020
Case

Minerva 2010: Turbulent Times

By: John R. Wells and Benjamin Weinstock

In 2010, amid a flurry of new discoveries, Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), raised $6.6 million to test her new cancer drugs in mice. It had been more than 6 years since she had announced that she and her small team at... View Details

Keywords: Biotechnology; Research; Product Development; Commercialization; Strategy

04 Sep 2018
First Look

New Research and Ideas, September 4, 2018

moral imperatives, we study the factors that influence when individuals find solutions that fall outside of the salient options presented. In particular, we study moral insight, or the discovery of solutions, other than selecting one of... View Details

Keywords: Dina Gerdeman

←
1
2
3
4
→